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Abstract
The Plasmodium falciparum PfA-M1 and PfA-M17 metalloaminopeptidases are validated
drug targets for the discovery of antimalarial agents. In order to identify dual inhibitors of
both proteins, we developed a hierarchical virtual screening approach, followed by in vitro
evaluation of the highest scoring hits. Starting from the ZINC database of purchasable com-
pounds, sequential 3D-pharmacophore and molecular docking steps were applied to filter
the virtual ‘hits’. At the end of virtual screening, 12 compounds were chosen and tested
against the in vitro aminopeptidase activity of both PfA-M1 and PfA-M17. Two molecules
showed significant inhibitory activity (low micromolar/nanomolar range) against both pro-
teins. Finally, the crystal structure of the most potent compound in complex with both PfA-
M1 and PfA-M17 was solved, revealing the binding mode and validating our computational
approach.
Introduction
According to recent statistics from the World Health Organization (WHO), malaria affects
more than 225 million individuals, causing approximately 600 000 deaths each year [1]. The
parasite P. falciparum is the most lethal of the Plasmodium species that cause human disease
[2]. Clinical disease symptoms, including fever, headache, anemia, respiratory distress and
blockage of deep capillaries, are caused by a repeated cycle of erythrocyte invasion and lysis by
asexual blood stage parasites. The majority of current therapies target this stage of the parasite
life-cycle [3]. The lack of an effective vaccine and emerging resistance to front-line antimalari-
als, including the artemisinins, poses a global public health threat and demands the develop-
ment of next generation antimalarial agents [4].
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One pathway that has attracted the attention of antimalarial drug discovery efforts is the
catabolism of erythrocyte hemoglobin, which is catalyzed by several enzymes and therefore
presents a number of potential therapeutic targets [3]. Among these novel targets are the ami-
nopeptidase enzymes that remove N-terminal amino acids from short peptides with high speci-
ficity. The P. falciparum alanyl aminopeptidase, PfA-M1, and leucyl aminopeptidase,
PfA-M17, act in concert to mediate the final stages of hemoglobin digestion [5,6]. PfA-M1 has
broad substrate specificity, preferentially cleaving P1 residues Leu, Ala, Arg and Lys; however,
it can also cleave Phe, Tyr, Asn and Ser [7]. In contrast, PfA-M17 demonstrates a restricted
specificity for Leu and, to a lesser extent, Ala [8, 9]. The active sites of PfA-M1 and PfA-M17
coordinate essential zinc ions that are required for the catalytic mechanism. PfA-M1 coordi-
nates a single zinc metal ion, while PfA-M17 contains two metal binding sites [10]. The two
aminopeptidases are each encoded by non-homologous genes and have been validated in vitro
and in vivo as drug targets, as inhibition of their activity can control both murine and labora-
tory malaria parasites [10]. Previous work within our group has identified potent dual inhibi-
tors of the enzymes [7, 9, 11–14], which bind via coordination of the zinc ions by a zinc
binding group (ZBG).
Virtual screening is now established as a valuable tool in early drug discovery, allowing fast
and economical selection of “hit” molecules before, subsequent experimental validation of the
virtual hits. This biological validation is absolutely required; indeed, in recent years several vir-
tual screening campaigns have been undertaken, with many papers reporting “hits” from vir-
tual screens that haven’t been evaluated experimentally [15,16]. Virtual screening can add
significant value to a drug discovery campaign; however, it demands careful attention to meth-
odology with regard to design, validation and experimental confirmation of the computational
results.
We were interested to evaluate whether a virtual screening study could identify novel mole-
cules that are capable of dual inhibitors of both PfA-M1 and PfA-M17. To this end, we under-
took a virtual screen of the ZINC database of purchasable subsets (~18 millions of compounds)
[17,18] and used successive 3D-pharmacophore and molecular docking to filter the virtual
‘hits’. Our screen identified 12 compounds that satisfied both the 3D-pharmacophore and
docking requirements. We investigated the inhibitory properties of the 12 compounds against
the aminopeptidase activity of both PfA-M1 and PfA-M17 in vitro, and demonstrated that that
two compounds were dual PfA-M1/PfA-M17 inhibitors. Finally, we determined the crystal
structures of the most potent hit in complex with both PfA-M1 and PfA-M17. Despite some
discrepancy between the predicted and experimentally determined poses of the most potent
hit, the obtained results demonstrate that, overall, the presented virtual screening protocol was
able to effectively identify dual inhibitors for PfA-M1 and PfA-M17.
Materials and Methods
Structure-based virtual screening
Generation of a structure-based pharmacophore model. The structure-based pharmaco-
phore model was generated using LigandScout software package v.3.0 [19]. The models were
generated from PDB codes 3EBH and 3EBI for PfA-M1, and 3KR4 and 3KR5 for PfA-M17 [6–
9]. We superposed the two inhibitors bestatin and hPheP[CH2]Phe for both drug targets and
generated a shared-features 3D pharmacophore. The pharmacophore model was validated by
screening with a manually generated database of compounds having bestatin and hPheP[CH2]
Phe seeded into 100 decoys from DUD-E decoy compounds database [20]. During the initial
validation step, the first generated pharmacophore model was associated with poor perfor-
mance. Therefore, pharmacophore maps were manually modified by systematically including/
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removing features, by increasing/reducing features tolerance and by adjusting the exclusion
volume spheres, in order to extract only bestatin and hPheP[CH2]Phe from the database of
decoys.
Virtual screening. Virtual screening was carried out using ZincPharmer [18] and
LigandScout software package v. 3.1 [19], using the previously obtained pharmacophore mod-
els, to search the Zinc database of fixed conformers [17]. A maximum of 0.5 Å Root Mean
Square Deviation (RMSD) from sphere centers, 10 rotatable bonds cut-off and molecular
weight in the range of 180–500 Daltons were used as input parameters for ZincPharmer. Com-
pounds were considered potential hits and retrieved for further analysis if they satisfied at least
(n/2) + 1 features of the pharmacophore models.
Docking settings. The compounds retrieved from the pharmacophore search were used
as input for a docking study. Molegro Virtual Docker ver. 5.5 (MVD) [21] and FlexX [22] were
used for a more accurate prediction, compared to pharmacophore search, of the binding mode
inside the active site of PfA-M1 and PfA-M17. An initial re-docking of bestatin and hPheP
[CH2]Phe into the active sites of the two aminopeptidases was carried out with MVD, in order
to define the correct parameters to be used during the simulations. The final selected values for
grid center were: X = 75.94 Y = 65.02 Z = 76.45 for PfA-M1 and X = 88.03 Y = 74.43 Z = 29.88
for PfA-M17, respectively. The grid sphere radius was set to 12.0 Å in both systems. The “Mol-
dock” [21] optimizer algorithm was chosen as a search algorithm using the following values: 10
numbers of run; 50 number of individuals in the population; water molecules were excluded
from the docking simulations. A second docking simulation was carried out with FlexX, a tool
implemented in the Lead-It software package (1Biosolve IT) that is specifically suited for pre-
dicting coordination geometries in zinc containing metalloproteins. The active site was defined
including all residues within a 10.0 Å radius sphere from the center of the mass of the ligand.
The clash factor was set to 0.6. Others parameter were kept as default [22].
Post-filtering of docking results. The virtual molecule hits obtained from the docking-
based virtual screening step were re-ranked according to their RMSD, considering only those
compounds with a similar pose in both docking tools (RMSD< 2.0 Å). The top-ranked poses
were re-assessed using the “Hyde” scoring function implemented in the Lead-It software pack-
age [23]. 12 hits were chosen on the basis of the estimated free-energy of binding and purchase
availability.
Biochemistry
Expression, purification and enzyme assays. The expression and purification of PfA-M1
and PfA-M17 in Escherichia coli employed a two-step purification process of Ni-NTA-agarose
column, followed by size exclusion chromatography on a Superdex 200 16/60 using an AKTAx-
press high throughput chromatography system (http://proteinexpress.med.monash.edu.au/
index.htm), as previously described [12,13]. Compounds were purchased from Ambinter
(France). Purity (90% or higher) of these compounds was confirmed by vendors. Aminopepti-
dase activity and Ki values for both enzymes were determined as already described [14,15].
Crystallization, data collection, structure solution and refinement. Crystals of the
PfA-M1 and PfA-M17 in complex with compound 12 were obtained by soaking as described
previously [12, 13]. Briefly, PfA-M1 was concentrated to 8.0 mg/mL in 50 mMHepes pH 8.0,
300 mMNaCl and 5% glycerol. Unliganded crystals were grown by hanging-drop vapour diffu-
sion, in 20% PEG8000, 0.2MMgCl2, 0.1M Tris pH 8.5, and 10% glycerol. The crystallisation
solution was supplemented with 2 mM of compound 12 to make the soak solution. Crystals
were soaked in compound soak solution overnight prior to data collection. PfA-M17 was con-
centrated to 13 mg/mL in 50 mMHepes pH 8.0, 300 mMNaCl. Unliganded crystals were
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grown in 40% PEG400, 0.1M Tris pH 8.4, and 0.2M LiSO4. The crystallisation solution was
supplemented with 2 mM of compound 12 and 1 mM ZnSO4 to make the soak solution, in
which they were soaked for 2 days prior to data collection. Data were collected at 100 K using
synchrotron radiation at the Australian Synchrotron using the macro-crystallography MX1
beamline 3BM1 for PfA-M1 [24], and the micro-crystallography beamline for PfA-M17. Dif-
fraction images were processed and integrated using iMosflm [25] (PfA-M1) or XDS [26]
(PfA-M17) and scaled using aimless from the CCP4 suite [27]. The model was refined in Phe-
nix [28] and manually built into electron density using Coot [29]. Summary statistics are pro-
vided in Table 1. The structures were deposited in the protein databank with accession codes
4ZQT and 5CBM.
Results
Generation of 3D-pharmacophore hypotheses
With the aim of pinpointing the necessary key features of a potential dual PfA-M1 and
PfA-M17 inhibitor, a pharmacophore hypothesis was generated for each target. We started
Table 1. Data collection and refinement statistics.
PfA-M1–12 PfA-M17–12
PDB ID 4ZQT 5CBM
Data collection
Resolution range (Å) 62–1.98 (2.05–1.98) 49–2.30 (2.33–2.30)
Space group P212121 P212121
Unit cell a = 75.4; b = 109.1; c = 118.1 α = β = γ = 90° a = 174.1; b = 177.7; c = 231.0 α = β = γ = 90°
Total reflections 762957 (68374) 2509800 (122968)
Unique reflections 68268 (6667) 315610 (15462)
Multiplicity 11.2 (10.3) 8.0 (8.0)
Completeness (%) 99.9 (99.3) 99.9 (99.7)
Mean I/sigma(I) 20.0 (2.5) 4.9 (1.1)
R-merge 0.678 (1.90) 0.482 (3.64)
R-meas 0.711 0.516
CC1/2 0.853 (0.388) 0.982 (0.446)
Refinement statistics
R-work 0.1626 0.1821
R-free 0.2080 0.2346
# of non-hydrogen atoms 8179 50850
macromolecules 7241 46963
ligands 35 194
solvent 903 3693
RMS(bonds) 0.008 0.008
RMS (angles) 0.99 1.09
Ramachandran favored (%) 98 97
Ramachandran outliers (%) 0.11 0.24
Clashscore 4.17 3.39
Average B-factor 23.60 26.91
macromolecules 22.40 26.60
ligands 27.10 (28*) 20.15 (24*)
solvent 33.60 31.82
Molprobity Score 1.2; 100th percentile (N = 12290, 1.98 Å ± 0.25Å) 1.4; 99th percentile (N = 8909, 2.30 Å ± 0.25Å)
* After an additional round of refinement including TLS parameters.
doi:10.1371/journal.pone.0138957.t001
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from two well-characterized dual inhibitors, bestatin (2-(3-amino-2-hydroxy-4-phenyl-butyry-
lamino)-4-methyl-pentanoic acid) and hPheP[CH2]Phe, a phosphinate dipeptide analogue, for
which high-resolution structures were available [7, 9], to derive a 3D-pharmacophore map rep-
resenting the main interactions between the enzymes and inhibitors (Fig 1).
For PfA-M1, the resulting map showed a total of eight pharmacophore features (Fig 1A &
1B). These included two hydrophobic patches (pointing towards the hydrophobic clefts formed
by residues Met1034, Tyr575, Val459, Ala461 and Glu519) and three charged patches (one
positively charged, deriving from the potential interaction with residues Glu319 and Glu519,
and two negatively charged, arising from the interaction with the zinc ion and Arg489). Hydro-
gen bonding donors and acceptors were also observed at Ala461 and Gly460 (acceptors) and
Tyr580 (donor). For PfA-M17 (Fig 1C & 1D) six points of interest were included in the phar-
macophore map: two hydrophobic points (formed by Met369, Phe398, Met392); a negatively
charged feature (pointing to Lys386); a positively charged feature (near Asp379 and Glu461); a
Fig 1. Pharmacophore hypotheses for PfA-M1 and PfA-M17. Protein backbone is shown as grey (loops) and cyan (strands and helices) ribbons. The
residues interacting with the pharmacophore maps are represented as ball and sticks, and colored by atom type. Bestatin is represented in violet, while
hPheP[CH2]Phe is in cyan. A) Superposition of bestatin and hPheP[CH2]Phe in the PfA-M1 active site. B) PfA-M1 obtained shared pharmacophore map,
which consists of the following features: F1 and F8 hydrophobic features, F2 hydrogen bond donor feature, F3 positively charged feature, F4 and F7
hydrogen bond acceptor features, F5 and F6 negatively charged features. C) Superposition of bestatin and hPheP[CH2]Phe in the PfA-M17 active site. D)
PfA-M17 obtained shared pharmacophore map, which consists of the following features: F1 and F6 hydrophobic features, F2 positively charged feature, F3
hydrogen bond donor feature, F4 negatively charged feature, F5 hydrogen bond acceptor feature.
doi:10.1371/journal.pone.0138957.g001
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hydrogen bond donor (pointing to Thr486); a hydrogen bond acceptor (interacting with the
main-chain of Gly489).
The two pharmacophore maps were then used to screen the ~18 million purchasable com-
pounds of the ZINC database [17] using a hierarchical screening protocol (Fig 2). The initial
screen of the ZINC database with the PfA-M1 pharmacophore map identified 859 molecules
that satisfied the required pharmacophore features. From the results of this screen, a new data-
base of conformations was generated, and subsequently screened against the PfA-M17 phar-
macophore map. This filtered screen identified 68 molecules that satisfied our requirements
Fig 2. Virtual screening workflow.
doi:10.1371/journal.pone.0138957.g002
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for both pharmacophores (Table A in S1 File). The obtained virtual hits were each visually
inspected to check the presence of a known zinc-binding group (ZBG), as would be expected
for a potential PfA-M1/PfA-M17 inhibitor.
Molecular docking
The 68 molecules that satisfied the critical features of PfA-M1 and PfA-M17 pharmacophores
were then investigated further by molecular docking. Compounds were filtered using two dis-
tinct docking tools, Molegro Virtual Docker (MVD) [21] and FlexX [22]. First the 68 virtual
hits were docked to PfA-M1 and PfA-M17 using MVD. On the basis of the Moldock score
[21], as well as the ability of these compounds to coordinate the zinc ions of the catalytic sites
of PfA-M1 and PfA-M17 (evaluated by visual inspection), 22 molecules were discarded
(Table A in S1 File). The remaining 46 molecules were then subjected to a second docking sim-
ulation using FlexX [22]. Docking of metalloproteins still remains a challenge due to the multi-
ple coordination geometries of the zinc ion and the lack of specific force field parameters to
model the metal-ligand interactions [30]. In this scenario, FlexX is described as being able to
detect and assign the statistically significant docking poses while simultaneously selecting the
best metal coordination geometry. All ligand poses resulting from FlexX docking were further
inspected in order to determine if they were similar to the MVD poses. Nine poses were
rejected because they had a RMSD> 2.0 Å compared to MVD poses. A total of 37 drug-like
molecules showed comparable poses when docked with both MVD and FlexX (RMSD< 2.0 Å
on superposed heavy atoms) in PfA-M1 and PfA-M17 binding sites. To rank the 37 virtual hits
we used the Hyde scoring function [23] to predict the binding affinity of each compound to
PfA-M1 and PfA-M17 (Table A in S1 File). This scoring function takes into account the zinc
coordination geometry contribution in the estimation of the binding affinity [23]. On the basis
of the binding affinity predicted with the Hyde scoring function, and final visual inspection, we
selected 12 molecules to investigate in vitro (Table B in S1 File).
Evaluation of the inhibitory activity of selected compounds against
PfA-M1 and PfA-M17
The top 12 hits identified in the virtual screen were evaluated for their ability to inhibit both
PfA-M1 and PfA-M17 in vitro. We initially tested the total aminopeptidase activity (as reported
by the fluorigenic substrate L-leucyl-7-amido-4-methylcoumarin) in the presence of 1 mM
compound (Fig 3). In this screen, the “no compound” control was considered 100% activity
and bestatin was included as an indicator/control for inhibition. From the results obtained,
only compounds 4 (ZINC ID: 25108749) and 12 (ZINC ID: 4090432) were able to inhibit the
activity of the enzymes to> 50%. Compound 4 was capable of 95% inhibition at 1 mM, while
12 showed 98% inhibition at 1 mM (Fig 3). The two inhibitory compounds were further ana-
lyzed to identify their effects on the individual aminopeptidases. To do this, we performed
dose-response assays for each inhibitor with each enzyme, and then determined a Ki via Dixon
plots (Fig 4). The most potent inhibitor was compound 12, with a Ki of 2.3 μM for PfA-M1 and
17.0 nM for PfA-M17. Compound 4 was a weaker inhibitor of both enzymes with Ki’s in the
micromolar range (Ki = 30.0 μM for PfA-M1 and 0.7 μM for PfA-M17; Fig 4). Both compounds
showed a competitive inhibition profile for each enzyme.
Docking analysis of compounds 4 and 12
Compounds 4 (3-{[amino(phenyl)methyl](hydroxy)phosphoryl}-methyl propanoic acid) and
12 (2-({[amino(phenyl)methyl]hydroxy)phosphoryl}methyl)4-methylpentanoic acid) are both
organophosphorus acid compounds, well known to be effective metal chelating agents [13].
Identification of New Inhibitors for M1 and M17 Aminopeptidases
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The binding mode of each compound was predicted by computational docking (Fig 5). The
orientation of the poses obtained with compound 4 in the active site of PfA-M1 and PfA-M17
fromMVD are comparable with those of FlexX (RMSD between compound 4 poses in
PfA-M1: 0.8 Å; RMSD between compound 4 pose in PfA-M17: 0.9 Å). The best poses of com-
pound 4 in PfA-M1 and PfA-M17 active sites are depicted in panel A and B of Fig 5. In the
PfA-M1 active site, compound 4 was predicted to form the following interactions: a phosphinic
oxygen atom coordinates the zinc and is hydrogen-bonded to the side chain of Tyr580; the
amino group forms interactions with Glu319 and Glu463. The aromatic ring forms favorable
hydrophobic interactions with Tyr575, Gln317 and Val459. The methyl group is accommo-
dated in the hydrophobic cleft formed by Tyr580 and Gly460. Additionally, a hydrogen bond is
formed between the oxygen of the carboxylic group and Gly460. The coordination geometry of
the zinc ion predicted by FlexX is a trigonal bypiramid.
The molecular docking of compound 4 in PfA-M17 predicts that: (1) the negatively charged
phosphinic oxygen coordinates one of the zinc ions and interacts with Lys374 and Lys386, (2)
the amino group forms hydrogen bonds with Thr486 and Asp399, and (3) a additional
Fig 3. Total aminopeptidase activity in the presence of 12 virtual screen compounds. The graph shown indicates the percentage of total
aminopeptidase activity in the presence of 1 mM of compound (as indicated). Bestatin was used as control.
doi:10.1371/journal.pone.0138957.g003
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hydrogen bond is formed between Gly489 and the phospinic oxygen. The pose is further stabi-
lized by hydrophobic interactions between the aromatic ring and Met392, Met396, Leu487 and
Ala577.
The best poses of compound 12 in PfA-M1 and PfA-M17 active sites are depicted in panel
C and D of Fig 5. Again, a reasonably similar binding mode was observed from the two differ-
ent docking tools (RMSD for PfA-M1: 1.1 Å; RMSD for PfA-M17: 1.5 Å). Compound 12 in
PfA-M1 active site is predicted to coordinate the zinc ion with the negatively charged oxygens
of its phosphinic group, which interact also with Tyr580. Glu319 and Glu463 form hydrogen
bonds with the amino group and the pose is further stabilized by a hydrogen bond between
Gly460 and the oxygen of the carboxylic group. Hydrophobic interactions are observed
between Gly317, Tyr575, Val459, Ala461 and the aromatic ring, and additionally between the
methyl group and Glu497. The compound is extended into the hydrophobic cleft, filling the S1
subsite of the large active site cavity.
Fig 4. Dixon plots of 1/V (y axis) versus inhibitor concentration (x axis) for PfA-M1 (top panel) and PfA-M17 (bottom panel). For PfA-M1, substrate
concentrations were 20 μM (blue) and 40 μM (red); inhibitor concentration in μM. For PfA-M17, substrate concentrations were 5 μM (magenta) and 10 μM
(green); inhibitor concentration in μM or nM as indicated. The point of intersection (-Ki) is indicated as a dotted line. (A) PfA-M1 and compound 4. (B) PfA-M1
and compound 12. (C) PfA-M17 and compound 4. (D) PfA-M17 and compound 12
doi:10.1371/journal.pone.0138957.g004
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Compound 12 was docked into the PfA-M17 active site with its the aromatic ring in the
hydrophobic cleft formed by residues Met392, Met396, Phe398, Ala577, Gly489. The two zinc
ions of PfA-M17 are coordinated by one of the oxygens of the phosphinic moiety and by one of
the oxygen atoms of the carboxylic group of compound 12, while the other oxygen of the car-
boxylic group is hydrogen-bonded to Lys386. The amino group of compound 12 forms a
hydrogen bond with Thr486. The aliphatic hydrophobic tail is extended in the apolar cleft, fill-
ing the S1 subsite of the active site cavity.
Crystal structures of PfA-M1 and PfA-M17 in complex with compound 12
The X-ray crystal structures of the potent compound 12 in complex with both PfA-M1 and
PfA-M17 were solved to a resolution of 2.0 and 2.3 Å respectively (Table 1). Compared to unli-
ganded PfA-M1 (PDB ID: 3EBG), no gross rearrangement was observed upon binding of com-
pound 12. Examination of PfA-M1 in complex with compound 12 revealed the molecular basis
for the inhibitory activity of this compound. The inhibitor coordinates zinc through the oxygen
atoms of the phosphinate group (Fig 6A). The oxygen of the central phosphinate moiety also
forms hydrogen bond interactions with Tyr580, and the amino group forms hydrogen bonds
with Glu319, Glu519 and Glu463. Furthermore, a hydrogen bond is formed between Gly460
and the oxygen of the carboxylic group. The aromatic ring forms favorable hydrophobic con-
tacts with Val459, Met462 and Tyr575. In total, the compound forms five hydrogen bonds and
is further stabilized by hydrophobic interactions.
Superposition of the compound 12 crystallographically determined binding pose with those
predicted by FlexX and MVD, show strong agreement between the computationally predicted
Fig 5. Molecular docking of compounds 4 and 12 shows the predicted bindingmode.Compound 4 is shown bound to PfA-M1 (A) and PfA-M17 (B);
compound 12 is shown bound to PfA-M1 (C) and PfA-M17 (D). Residue names are indicated.
doi:10.1371/journal.pone.0138957.g005
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binding modes and the crystallographic data (Fig 6B). The zinc-binding group is in the same
position in all the three cases and there is only a small difference in the position of the aromatic
ring, which is rotated in the pose predicted by MVD. The highest correspondence between
docking pose and crystal structure was obtained with FlexX software.
In PfA-M17, compound 12 binds with a different chirality (R) at its C11 atom, compared to
the topologically equivalent atom ((S)-C19) of its structural analogue hPheP[CH2]Phe, bound
to PfA-M17 (PDB Code: 3KR5) (Fig 6C). With such chirality, compound 12 is still able to ori-
ent its amino moiety towards Asp399 (interacting with the latter via a hydrogen bond) and at
Fig 6. X ray crystal structures of compound 12 bound to PfA-M1 and PfA-M17. (A) View from the top of the catalytic pocket, showing compound 12 and
the main interactions in the PfA-M1 active site (in green). (B) Structural alignment of compound 12 as experimentally determined (green), FlexX-based pose
(in blue) and MVD-based pose (in pink). (C) View from the top of the catalytic pocket, showing compound 12 (green) and the main interactions in the PfA-M17
active site. (D) Structural alignment of compound 12 as experimentally determined (green), and the most similar predicted pose (pink).
doi:10.1371/journal.pone.0138957.g006
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the same time to direct the phenyl substituent towards the hydrophobic pocket formed by
Met392, Met396, Phe398, Gly489, Leu492 and Ala577. As in the case of hPheP[CH2]Phe, both
zinc ions of PfA-M17 are tightly coordinated to one or both of the phosphinate oxygens of
compound 12, and the latter can also form a hydrogen bond to the catalytic carbonate. Disor-
dered electron density for the carboxylate and leucyl substituents of compound 12 is observed
in all twelve chains of the PfA-M17 binding pockets, indicating substantial flexibility of bind-
ing. As a result, the complete compound could be build in only one of the active sites (Chain
E), and even then could only be modeled with half occupancy for the flexible carboxylate and
leucyl groups. In this pose, the carboxylate forms a hydrogen bond with the main chain amine
of Gly489, while the aliphatic leucyl group makes no interactions and is exposed to solvent.
In contrast to the structure of PfA-M1 bound to compound 12, there is some discrepancy
between the docked and crystallographically determined binding poses of compound 12 bound
to PfA-M17 (Fig 6D). Unlike the experimentally determined structure, the docked pose shows
that only a single zinc is coordinated by the phosphinic moiety. The amine moiety is also ori-
ented differently: rather than forming a hydrogen bond with Asp399, it is directed in the oppo-
site direction and forms hydrogen bonds to the main chain oxygen atoms of Thr486 and
Leu487. Irrespective of the different zinc coordination, the phenyl substituent of compound 12
is bound in largely the same position in the docked structure compared to the crystal structure,
sandwiched between Met396 and the main chain of Gly489. Finally, the docked structure
showed few interactions between the leucyl tail of compound 12 and the binding pocket. This
lack of binding interactions is also observed in the crystal structure, and accounts for the flexi-
bility of this compound region. Composite OMIT maps of compound 12 when bound to M1
and M17 (S1 Fig) were consistent with our previous observations and showed discorded elec-
tron density of the Leu sidechain when in complex with both M1 and M17. This indicates that,
similarly to the compound 12-M17 binding conformation, there is flexibility of binding also in
compound 12-M1.
Discussion
Malaria is currently one of the most deadly infectious human diseases [1]. Emerging resistance
to front-line antimalarials, including the artimisinins, presents an urgent need for new antima-
larial drugs. PfA-M1 and PfA-M17 are essential for parasite survival and are validated antima-
larial drug targets [7–10]. To date, different inhibitor scaffolds have been described as
competitive dual inhibitors of PfA-M1 and PfA-M17, including peptide-based bestatin ana-
logues, phosphinopeptides and phosphonic acids [7–9, 11–14]. Recently, our group has also
identified hydroxamic acid containing compounds as potent inhibitors of PfA-M1 and
PfA-M17 that show anti-parasitic activity in the nanomolar range [12].
In the present study, we explored the ability of a new structure-based virtual screening pro-
tocol to identify dual inhibitors of PfA-M1 and PfA-M17. Virtual screening is highly desirable
for structure-based drug design (SBDD) in that it potentially has the ability to rapidly acceler-
ate and economize drug discovery. Computational approaches can identify potential hits in a
fraction of the time and effort that is required for high-throughput in vitro screening
approaches. However, despite a number of successful SBDD studies that have incorporated in
silico approaches [31,32], computational early lead discovery still suffers from several limita-
tions [33, 34]. This is largely a result of in silico results not being experimentally validated and
therefore methodologies and approaches are not evolving as is required. The ultimate proof of
concept required for molecular docking and virtual ligand screening is represented by the
experimentally determined structure of the complex between the target and virtual hits, which
is rarely determined and published [31, 32].
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The main goal of our current work, therefore, is twofold, i) the identification of novel dual
inhibitors of PfA-M1 and PfA-M17 and ii) the experimental validation of the applied struc-
ture-based virtual screening protocol. Starting from the available structural data, two pharma-
cophore hypotheses have been developed, and used to screen the ZINC database.
Subsequently, a docking simulation has been carried out using two different docking tools, and
several filters have been applied to finally select promising hits. We identified twelve com-
pounds that satisfied all the filtering criteria. Interestingly, some of them contain chemical scaf-
folds already associated with other metalloaminopeptidase inhibitors, providing a further
validation of the computational results. Two of the identified molecules demonstrated inhibi-
tory activity for both PfA-M1 and PfA-M17. In particular, compound 12 acted as a low nano-
molar PfA-M17 inhibitor (Ki = 17.0 nM). The comparison of crystal structure of the
phosphonic arginine mimetics compounds series [13] recently identified by our group with the
inhibitors identified herein shows a similar pattern of interactions with the zinc ion, involving
the oxygen atoms of the phosphonic/phosphinic moiety. Also, a hydrogen bond with Tyr580
and the O1 atom of the phosphinic/phosphinic group is conserved. The most potent inhibitor
of phosphinic arginine derivatives series showed a Ki = 104 uM for PfA-M1 and Ki = 11 nM for
PfA-M17. The higher potency of compound 12 as a PfA-M1 inhibitor (Ki = 2.3 uM) could
potentially be explained by the entropy gain of binding due to the lack of a flexible linker
between the aromatic moiety and the aminophosphinic moiety.
The crystal structure of PfA-M1 in complex with compound 12 further confirmed the valid-
ity of the computational screening described herein. In contrast to the structure of PfA-M1
bound to compound 12, we noticed some discrepancy between the docked and structurally
determined binding poses of compound 12 bound to PfA-M17. Investigating the reasons
underlying the disagreement between the docked and structurally determined binding poses of
compound 12 in complex with PfA-M17, we found that the original compound retrieved from
the ZINC Database (ZINC ID: 04090433) during the virtual screening process showed, at its
C11 atom, the same chirality (S) of its structural analogue hPheP[CH2]Phe. This is not surpris-
ing considering that the latter was used as a template to build the 3D-pharmacohopre map
used during the screening. The chirality difference between the docked compound and the
experimentally determined binding pose is, therefore, probably responsible for the observed
discrepancy. Indeed, as a consequence of the incorrect predicted chirality, the amino moiety of
ZINC04090433 cannot be oriented properly without causing the adjacent phenyl substituent of
the C11 atom to severely clash the active site residues Phe398 and Thr486. Moreover, with the
wrong C11 chirality and the phenyl moiety accommodated in the hydrophobic cleft formed by
residues Met392, Met396, Phe398, Gly489, Leu492 and Ala577, the phosphinate moiety of
ZINC04090433 results shifted of* 1.5Å from the experimentally determined position, thereby
losing a coordination site with the Zn ions of PfA-M17, and leaving the room for the carboxylic
group to coordinate the other Zn ion.
We are unable at the moment to provide a clear explanation to the inability of the 3D-phar-
macophore map to retrieve the right enantiomer (R) of compound 12 from the ZINC Database
(ZINC12888856). Nonetheless, a retrospective analysis of the docking results, in light of the
experimentally determined complex between M17 and compound (R)12, showed that a low
scoring pose of the (S) enantiomer of compound 12 (ZINC04090433) (S2 Fig) docked with a
conformation highly similar to (R)12, as experimentally determined. In this case however, the
aromatic moiety at C11 position of compound (S)12 is predicted to be too close to the aromatic
side chain of Phe398 (~3.0 Å), compared to the crystal structure (~3.5 Å) of (R)12. The latter
observation accounts for the low energy score observed for this pose.
Despite the overall success of our protocol, we did not identify a completely new chemical
scaffold or ZBG, as both our hit compounds coordinates the zinc ion through their
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phosphinate group, as previously described [13]. One of the possible reasons of this failure can
be related to the excessively stringent criteria imposed by the two pharmacophore maps. The
latter indeed may bias the results to compounds highly similar to the initial ones used to derive
the maps. Further, the presence of the metal ions in the active sites still represents a great chal-
lenge for currently available docking tools. For many docking scoring functions, which mostly
rely on non-bonded interactions, the partial covalent nature of metal-ligand interactions
remains problematic [30].
Despite these limits, the experimental validation of our results supports our computational
methodology. Compounds 4 and 12 were the top-ranking hits according to MVD and Hyde
scores. Moreover, there is a strong agreement between the predicted binding mode of com-
pound 12 to PfA-M1 and the crystallographic data.
Conclusion
Our described virtual screening protocol identified a potent dual inhibitor of the PfA-M1 and
PfA-M17 proteins. These results indicate that the virtual screening protocols can be success-
fully applied in other studies, and the obtained structure can be used as starting point for fur-
ther development and optimization of new lead molecules.
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